Spyre Therapeutics Inc (SYRE) Unusual Options Activity Today

Checking SYRE unusual options activity helps you spot when traders are making outsized bets on Spyre Therapeutics Inc before the broader market catches on. Spyre Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor SYRE unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching SYRE unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking SYRE unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and SYRE unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies.

In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Catalysts rarely arrive without a footprint, and SYRE unusual options activity is often where that footprint shows up first. Our scanner tracks Spyre Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at SYRE unusual options volume on the call side or chasing put sweeps, Spyre Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.